COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,510 Articles (22,870 medRxiv, 8,640 bioRxiv)

Most recent first Previous |  Page 2458: Articles 24571-24580  | Next

High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2
Vanhove, B., Duvaux, O., Rousse, J., Royer, P.-J., Evanno, G., Ciron, C., Lheriteau, E., Vacher, L., Gervois, N., Oger, R., Jacques, Y., Salama, A., Duchi, R., Perota, A., Delahaut, P., Ledure, M., Paulus, M., So, R., Mok, C. K. P., Bruzzone, R., Bouillet, M., Brouard, S., Cozzi, E., Galli, C., Blanchard, D., Bach, J.-M., Soulillou, J.-P.
10.1101/2020.07.25.217158 — Posted: 2020-07-25
Clustering, diffusion and evolution of COVID19 infections during lock-down
Bos, W., Bertoglio, J.-P., Gostiaux, L.
10.1101/2020.07.22.20159830 — Posted: 2020-07-25
SARS-CoV-2 differs from SARS-CoV in the requirements for receptor expression and proteolytic activation to trigger cell-cell fusion and is not inhibited by Bromhexine
Hörnich, B. F., Grosskopf, A. K., Schlagowski, S., Tenbusch, M., Neipel, F., Hahn, A. S.
10.1101/2020.07.25.221135 — Posted: 2020-07-25
β-Coronaviruses use lysosomal organelles for cellular egress.
Altan-Bonnet, N., Altan-Bonnet, G. Y., Ghosh, S., Dellibovi-Ragheb, T., Pak, E., Qiu, Q., Fisher, M., Takvorian, P., Bleck, C., Hsu, V., Fehr, A., Perlman, S., Straus, M., Whittaker, G., de Haan, C. A.
10.1101/2020.07.25.192310 — Posted: 2020-07-25 Discussion: Onsite
Factors Associated with COVID-19 Mitigation Behavior among US Adults
Lemke, D., Lemke, K.
10.1101/2020.07.20.20157925 — Posted: 2020-07-25
Confirmed and Unreported COVID-19 Death Counts: An Assessment of Reporting Discrepancy
Ahamad, M. G., Tanin, F.
10.1101/2020.07.20.20158139 — Posted: 2020-07-25 Discussion: Onsite
A vulnerability analysis for the management of and response to the COVID-19 epidemic in the second most populous state in Brazil
Campos, I. S., Aratani, V. F., Cabral, K. B., Limongi, J. E., Oliveira, S. V. d.
10.1101/2020.07.20.20158345 — Posted: 2020-07-25
Evaluating temperature and humidity gradients of COVID-19 infection rates in light of Non-Pharmaceutical Interventions
Choma, J., Mellado, B., Lieberman, B., Correa, F., Maslo, C., Naude, J., Ruan, X., Hayashi, K., Monnakgotla, K., Dahbi, S.-E., Stevenson, F. D.
10.1101/2020.07.20.20158071 — Posted: 2020-07-25
Dynamics of SARS-CoV-2 with Waning Immunity in the UK Population
Crellen, T., Pi, L., Davis, E., Pollington, T. M., Lucas, T. C. D., Ayabina, D., Borlase, A., Toor, J., Prem, K., Medley, G. F., Klepac, P., Hollingsworth, T. D.
10.1101/2020.07.24.20157982 — Posted: 2020-07-25 Discussion: Onsite
A data-driven metapopulation model for the Belgian COVID-19 epidemic: assessing the impact of lockdown and exit strategies
Coletti, P., Libin, P., Petrof, O., Willem, L., Steven, A., Herzog, S. A., Faes, C., Wambua, J., Kuylen, E. J., Beutels, P., Hens, N.
10.1101/2020.07.20.20157933 — Posted: 2020-07-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).